Johnson & Johnson Uses AI to Halve Drug Development Lead Time
Johnson & Johnson is leveraging AI to reduce the time required to generate drug development leads by half, according to the company's Chief Information Officer. The technology is also streamlining regulatory document preparation and manufacturing processes, though full AI-driven drug discovery is not yet achievable. The company emphasizes AI as a tool to enhance, not replace, employee roles.
Tickers: $JNJ
Topics: AI Applications Artificial Intelligence Drug Development Johnson & Johnson Pharmaceutical Industry